Valeant Pharmaceuticals Intl Inc (NYSE:VRX) announced today that it will pay down $125 million of senior secured loans, keeping it on track with …
Healthcare analysts take different approaches to valuing Transenterix and Valeant.
Fears about financial control should be a buying opportunity in Valeant stock, says Cantor.
Valeant Pharmaceuticals Intl Inc’s (NYSE:VRX) Ortho Dermatologics division announced results from the Pivotal Phase 3 long-term extension study (AMAGINE-2), which demonstrated that SILIQ™ (brodalumab) …
TEVA needs a long-term solution after MYL’s generic Copaxone approval; VRX works on its debt problem.
Valeant’s comeback progresses with new notes offering; RedHill ups the risk ante in favor of time/money.
Bausch + Lomb, a division of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), announced the introduction of Biotrue® ONEday for Astigmatism daily disposable contact lenses in 20 …
The hedge fund guru’s Q2 moves added ECYT gains to his pocket while saving him greater losses in VRX.
A glimpse into why Louise Chen believes Valeant is the better biotech play than Teva down the line.